FDA warned Thrive Health and Wellness, a Colorado repackager, that sterile drugs were made in unsanitary conditions and sold without approval.
What happened
FDA inspected the Englewood, Colorado facility from March 25 to April 3, 2025 and found serious gaps in how sterile drug products were made. Investigators saw staff fill sterile drugs into syringes on a benchtop in an ordinary, unclassified room that also held a blood sample centrifuge, with carpet on the floor, non-sterile gloves, exposed hair and skin, no sporicidal disinfectant, and no media fills ever performed. The firm stopped repackaging sterile drugs on April 21, 2025 and on May 21, 2025 recalled all repackaged sterile products dispensed between January 2 and April 18, 2025 because it could not assure sterility.
What FDA found
Staff filled sterile drugs into syringes on a benchtop in an unclassified room, not in an ISO 5 area (the cleanest air rating required for sterile filling), so the products could have been contaminated.
Section 501(a)(2)(A) of the FDCAThe staff doing sterile operations had never run a media fill, a test using nutrient broth to show the process can reliably make sterile product, so there is no assurance they can do it.
Section 501(a)(2)(A) of the FDCAThe aseptic processing area and surroundings had hard-to-clean surfaces, including carpet covering the entire facility floor.
Section 501(a)(2)(A) of the FDCAStaff performed aseptic work with non-sterile gloves and exposed hair and skin, and the firm used non-sterile wipes and no sporicidal disinfectant in the filling area.
Section 501(a)(2)(A) of the FDCAThe firm repackaged drugs such as NAD+ and MEGALean without any FDA-approved application for them, which makes them unapproved new drugs.
Sections 505(a) and 301(d) of the FDCAThe labels on these injectable drugs do not give adequate directions for use, so the products are misbranded.
Section 502(f)(1) of the FDCA
What FDA wants
Within 15 working days, the firm must write to FDA describing the specific steps taken to fix the violations, or state that it does not plan to resume making sterile drugs. If it does plan to resume, it must explain how it will prevent repeat violations, send supporting documents, and notify FDA 15 working days before restarting.
Who should pay attention
- clinics, med spas and pharmacies that bought repackaged injectables from this firm
- compounding pharmacies and repackagers that handle sterile drugs
- distributors and telehealth brands sourcing tirzepatide or NAD+ injections
This is a summary. Read the original letter on fda.gov.